Eloralintide + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoarthritis
Conditions
Osteoarthritis, Overweight or Obesity
Trial Timeline
Feb 9, 2026 → May 1, 2028
NCT ID
NCT07353931About Eloralintide + Placebo
Eloralintide + Placebo is a phase 3 stage product being developed by Eli Lilly for Osteoarthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07353931. Target conditions include Osteoarthritis, Overweight or Obesity.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07369011 | Phase 3 | Recruiting |
| NCT07392190 | Phase 3 | Recruiting |
| NCT07353931 | Phase 3 | Recruiting |
| NCT07321886 | Phase 3 | Recruiting |
| NCT07282600 | Phase 3 | Recruiting |
| NCT06916091 | Phase 1 | Completed |
Competing Products
20 competing products in Osteoarthritis